Q4 Archives -

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

https://pharmaphorum.com/views-analysis-sales-marketing/tecfideras-patent-pyrrhic-victory-biogen/

With the full year results season drawing to a close, Richard Staines asks who the winners were and

Q4 results roundup 2019

https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/

Mylan has reported lower than expected full year earnings and 2019 forecasts, thanks partly to delays in its

Mylan reports lower than expected earnings

https://pharmaphorum.com/news/mylan-reports-lower-than-expected-earnings/

Sanofi’s strategy of betting on new drugs and biotech acquisitions seems to be paying off, as the company

Sanofi expects growth as rare disease drugs boost earnings

https://pharmaphorum.com/news/sanofi-expects-growth-as-rare-disease-drugs-boost-earnings/

Q4